The tariff classification of Glide Ankle-Foot Orthosis (AFO) from China
No Headquarters ruling in this index revokes or modifies this ruling. That is not confirmation that it is still in effect: this index does not hold every Headquarters ruling. Confirm its current status with CBP before relying on it (ruling on CBP CROSS). Text last read from CBP on Nov 21, 2026.
Key passages, quoted from the ruling
- The applicable subheading for the Glide AFO will 9021.10.0090, Harmonized Tariff Schedule of the United States (HTSUS), which provides for “Orthopedic appliances …: Orthopedic or fracture appliances, and parts and accessories thereof: Other.” The general rate of duty will be free.
Ruling text
In your letter dated July 23, 2026, you requested a tariff classification ruling. Elevate Glide Ankle-Foot Orthosis (AFO) is a dorsiflexion-assist ankle-foot orthosis that supports the position of the foot and ankle for individuals unable to do so independently due to foot drop and reduced dorsiflexion.
It consists of a carbon fiber frame (comprising a foot plate and a lateral-anterior strut), a calf cuff, a CoolFlow liner fitting into the interior of the cuff, and a calf strap equipped with a BOA® Fit System, which allows the calf strap to be adjusted via a dial. You explain that this support restores proper gait mechanics, enhances mobility, and improves stability and balance, thereby reducing the risk of falls.
By facilitating a more normal gait, supporting the lower limb, and helping maintain proper posture and alignment, the Glide AFO also minimizes strain on muscles and joints, including the knees, hips, and back, which reduces pain and fatigue. The Glide AFO is available in both right and left foot models and is fully adjustable. The AFO is imported in disassembled form together with product labeling, instructions for use, a patient care guide, warnings, warranty information, and fitting tools.
All components and materials are packed in an “on-the-go” package. You claim that foot drop is a physical impairment that substantially limits one’s ability to walk. The Glide AFO is a specially designed ambulatory aid engineered to assist individuals with mobility impairments caused by foot drop. Any other use is speculative and fugitive. The Glide AFO lifts the front of the foot via dorsiflexion assistance, enabling the foot to achieve adequate ground clearance during the swing phase of walking.
The result is a more natural gait and a reduced risk of trips and falls. The Glide AFO’s carbon fiber footplate limits excessive downward movement of the forefoot (known as plantar flexion), while managing weight distribution and energy transfer during walking. Its anterior shell and lateral-anterior carbon fiber strut deliver dynamic ground reaction force, connecting the footplate to the calf cuff to enhance stability while supporting the tibia.
The calf cuff and BOA strap secure the AFO to the upper lower leg, ensuring it fits properly to provide the prescribed sagittal-plane dorsiflexion support, while the CoolFlow liner and tibia shims enhance comfort to support extended wear. You explain that the product’s physical properties are not useful to the general public. The design, form, and corresponding use of the Glide AFO designate it as an article designed to address the symptoms of foot drop that would provide no benefit to non-handicapped persons.
Further, the design, materials, cost, and warranty of the Glide AFO make it overwhelmingly more beneficial and probable for use by individuals with permanent or chronic foot drop, as opposed to those with acute or transient cases. You state that Elevate is a recognized manufacturer of AFOs and similar ambulatory aids for individuals with foot drop and is known for its innovative products that provide dynamic support for those experiencing mobility challenges.
The text above is an excerpt. The official ruling, with its letterhead, signature and any attachments, is on CBP CROSS (N363602).